• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Bay­er drops an Io­n­is-part­nered drug af­ter sink­ing $240M in­to its de­vel­op­ment

3 years ago
Deals
R&D

Am­gen on IRA's drug price ne­go­ti­a­tions: 'Ma­te­r­i­al ad­verse ef­fec­t' on sales, busi­ness and op­er­a­tions

3 years ago
Pharma

Af­ter a one-year gap, Sage fi­nal­ly finds new CMO; Gut­ted by lay­offs, Flag­ship's Ru­bius reshuf­fles a not-so-full deck

3 years ago
Peer Review

Sanofi, As­traZeneca clinch first OK for RSV an­ti­body — just as vac­cines line up at reg­u­la­tors

3 years ago
Pharma
FDA+

Ex­clu­sive: Mt. Ever­est al­most got in the way of a tR­NA biotech, but hC Bio­science climbs to Se­ries A ex­ten­sion

3 years ago
Financing
Startups

Scoop: Call­ing off an IPO, a can­cer and Covid-19 vac­cine mak­er rais­es a Se­ries C

3 years ago
Financing
Startups

'For­ward, faster' and 200 jobs lighter as fi­bro­sis and kid­ney dis­ease get cut, Gala­pa­gos CEO Stof­fels once again ...

3 years ago
People
Deals

Mer­ck con­fronts stig­ma and fear around lung can­cer screen­ing in ed­u­ca­tion­al cam­paign

3 years ago
Pharma
Marketing

Re­gen­eron culls two drugs from pipeline amid dou­ble-dig­it rev­enue drop af­ter Covid mAb cock­tail pull

3 years ago
Pharma

With drug price ne­go­ti­a­tions in the books, Dems turn to launch prices as the next chal­lenge

3 years ago
Law

As­traZeneca pulls pa­tient da­ta ex­posed on code shar­ing site GitHub

3 years ago
Pharma

Bio­phar­ma com­pa­nies to FDA: In­ter­na­tion­al­ly har­mo­nize plans to stan­dard­ize safe­ty da­ta and analy­sis

3 years ago
FDA+

FDA still not ready to go back to ac­tu­al in-per­son meet­ings with bio­phar­ma spon­sors

3 years ago
FDA+

Mod­er­na's stock plunges in pre­mar­ket trad­ing as Ban­cel promis­es com­pa­ny is in 'much bet­ter place' for FY23 de­liv­er­ies

3 years ago
Pharma

Texas CD­MO is cut­ting 60% of staff as fo­cus shifts to drug dis­cov­ery, in-house can­di­dates

3 years ago
Pharma
Manufacturing

Man­u­fac­tur­ing roundup: Teru­mo Phar­ma­ceu­ti­cal So­lu­tions ex­pand­ing CD­MO reach out­side Japan; EU­ROAPI boost­ing ...

3 years ago
Manufacturing

Up­dat­ed: Cit­ing ef­fi­ca­cy, GSK halts UTI an­tibi­ot­ic tri­al ear­ly, plans to file for FDA ap­proval next year

3 years ago
R&D

Small start­up touts a PhI­II suc­cess in rare 'but­ter­fly skin' dis­ease af­ter an FDA hold rout­ed shares

3 years ago
R&D

Tri­ci­da eye­ing sale, cost-cut­ting op­tions af­ter fail­ing high-stakes CKD wa­ger

3 years ago
R&D

Af­ter pulling IPO plans, Arti­va part­ners with Af­fimed to speed up NK cell ther­a­py com­bo

3 years ago
Deals
R&D

'Do the right thing': Bil­lion­aire push­es strug­gling biotech to re­turn cash to in­vestors

3 years ago
People

Ex­sci­en­tia wants to bring its AI/ML ap­proach in­to the world of bi­o­log­ics. It's start­ing with an­ti­bod­ies

3 years ago
R&D
AI

Com­pass' sin­gle-dose psilo­cy­bin shows strong ef­fi­ca­cy in PhII treat­ment-re­sis­tant de­pres­sion tri­al

3 years ago
R&D

A Chica­go biotech skips the IPO in fa­vor of late-stage Se­ries D for a PhI­II Tourette drug

3 years ago
Financing
Startups
First page Previous page 428429430431432433434 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times